Barone, T. A., Burkhart, C. A., Safina, A., Haderski, G., Gurova, K. V., Purmal, A. A., . . . Plunkett, R. J. (2017). Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma. Neuro Oncol.
Citação norma ChicagoBarone, Tara A., Catherine A. Burkhart, Alfiya Safina, Gary Haderski, Katerina V. Gurova, Andrei A. Purmal, Andrei V. Gudkov, and Robert J. Plunkett. "Anticancer Drug Candidate CBL0137, Which Inhibits Histone Chaperone FACT, Is Efficacious in Preclinical Orthotopic Models of Temozolomide-responsive and -resistant Glioblastoma." Neuro Oncol 2017.
MLA citiranjeBarone, Tara A., et al. "Anticancer Drug Candidate CBL0137, Which Inhibits Histone Chaperone FACT, Is Efficacious in Preclinical Orthotopic Models of Temozolomide-responsive and -resistant Glioblastoma." Neuro Oncol 2017.